培美曲塞联合顺铂方案二线治疗晚期非小细胞肺癌的近期疗效观察

Pemetrexed combined with cisplatin for second-line therapy of advanced non-small cell lung cancer

目的探讨分析培美曲塞联合顺铂方案(PC方案)二线治疗晚期非小细胞肺癌的近期疗效及不良反应。方法对19例经过一线化疗之后出现复发或进展的晚期非小细胞肺癌患者,给予培美曲塞500mg/m2和顺铂75mg/m2,以21d为一个周期,在至少两周期以后进行疗效和不良反应的评价。结果在本组19例患者中,有效率为42.11%,主要不良反应为胃肠道反应及轻度骨髓抑制,经对症处理后得到有效的缓解,不影响后续化疗的进行。结论培美曲塞联合顺铂方案二线治疗晚期非小细胞肺癌,疗效较好,虽然不良反应的发生率略高,但多为轻度,耐受性较好,是二线治疗晚期非小细胞肺癌的理想方案之一。

Objective To investigate efficacy and untoward effect of pemetrexed combined with cisplatin（PC Program） for second-line therapy of advanced non-small cell lung cancer（NSCLC）.Methods 19 patients with advanced NSCLC who had received first-line therapy but had relapsed or progressed were given 500 mg/m2 of pemetrexed and 75mg/m2 of cisplatin,and 21 days were considered as one cycle,then evaluated the efficacy and untoward effect after two cycles at least.Results In 19 patients,the effective rate was 42.11%,the major untoward effect were disturbances of the digestive tract and lightly marrow toxicities while all patients came to remittence after symptomatic treatment,the following chemotherapy was not affected.Conclusion Pemetrexed combined with cisplatin for second-line therapy of advanced non-small cell lung cancer can reach a good efficacy,though the incidence of untoward effect was high,but most were lightly and tolerance.